Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
In STAT News, Mary Jo Lamberti, a research fellow at the Tufts Center for the Study of Drug Development, unveiled an analysis of the amount of time it takes to initiate a clinical trial.
Elizabeth Holmes, the founder of embattled biotech Theranos, and former company president Sunny Balwani have been charged with massive fraud by the U.S. Securities and Exchange Commission.
Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the U.S. House of Representatives.
Martin Shkreli’s actions were brash and often bizarre, but served as a catalyst for the pharma pricing debate.
AcelRx Pharmaceuticals plans to resubmit the NDA for Dsuvia in the second quarter of this year.
Abiomed, Inc. will pay the U.S. government $3.1 million to settle allegations that the company sought to influence doctors to use the company’s line of heart pumps in a kickback scheme.
Days before his sentencing for a criminal fraud conviction disgraced pharma entrepreneur Martin Shkreli has been ordered to forfeit $7.36 million.
With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.
Life science companies are popular targets for securities fraud litigation.